Myelofibrosis Therapeutics

PUBLISHED: August 16, 2024

PAGES: 136 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Myelofibrosis Therapeutics Market to Reach US$1.2 Billion by 2030

The global market for Myelofibrosis Therapeutics estimated at US$917.9 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$906.1 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$241.3 Million While China is Forecast to Grow at 3.4% CAGR

The Myelofibrosis Therapeutics market in the U.S. is estimated at US$241.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$188.4 Million by the year 2030 trailing a CAGR of 3.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global Myelofibrosis Therapeutics Market - Key Trends and Drivers Summarized

Myelofibrosis, a rare type of bone marrow cancer, disrupts the body’s normal production of blood cells, leading to severe anemia, weakness, fatigue, and splenomegaly. The therapeutics market for myelofibrosis has been evolving with a focus on advanced treatment modalities that offer better efficacy and improved quality of life for patients. The current treatment landscape includes a combination of drug therapies, bone marrow transplants, and emerging gene therapies. Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib, have become standard treatments due to their ability to reduce symptoms and improve overall survival rates. Research into novel therapeutic targets continues to expand, with promising candidates like bromodomain inhibitors and telomerase inhibitors undergoing clinical trials. These developments signify a robust pipeline of potential treatments that could revolutionize patient outcomes in the near future.

Recent advancements in molecular and genetic profiling have enhanced our understanding of the pathophysiology of myelofibrosis, leading to more precise and targeted therapeutic approaches. The integration of next-generation sequencing (NGS) and other advanced diagnostic tools enables the identification of specific mutations and molecular markers associated with the disease. This precision medicine approach not only helps in tailoring treatments to individual patients but also aids in monitoring disease progression and response to therapy. Moreover, the advent of combination therapies that utilize multiple drugs to target various pathways simultaneously shows great promise in overcoming drug resistance and achieving more durable responses. These innovative treatment strategies are reshaping the therapeutic landscape and providing new hope for patients suffering from this debilitating disease.

The growth in the myelofibrosis therapeutics market is driven by several factors. Key among them is the increasing prevalence of myelofibrosis and related myeloproliferative neoplasms, which has heightened the demand for effective treatments. Advances in biotechnology and pharmaceutical research have led to the development of more efficacious and targeted therapies, spurring market expansion. Patient awareness and advocacy are also playing a crucial role in driving market growth, as more patients seek advanced treatment options and participate in clinical trials. Additionally, favorable regulatory policies, including orphan drug designations and expedited approval processes, have incentivized companies to invest in myelofibrosis research and development. The rise in healthcare expenditure and improved access to healthcare services globally further supports market growth, as more patients gain access to cutting-edge therapies. Collectively, these factors are propelling the myelofibrosis therapeutics market towards significant growth and innovation.

Select Competitors (Total 86 Featured) -

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie, Inc.
Bristol-Myers Squibb Company
Disc Medicine
Galecto
Genentech, Inc.
Geron Corporation
GSK Plc
Incyte Corporation
Italfarmaco SpA
Kartos Therapeutics
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
Swedish Orphan Biovitrum AB;

Product Code: MCP26844

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Myelofibrosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Increasing Prevalence of Myelofibrosis Spurs Demand for Novel Therapeutics
- Advances in Molecular Profiling Propel Growth in Precision Medicine
- Next-Generation Sequencing Expands Addressable Market Opportunity
- Development of JAK Inhibitors Strengthens Business Case for Targeted Therapies
- Gene Therapy Innovations Generate New Market Opportunities
- Emergence of Combination Therapies Sustains Growth in Treatment Options
- Here's How Advanced Clinical Trials are Shaping the Therapeutics Landscape
- Adoption of Precision Medicine Approaches Spurs Growth in Tailored Therapies
- Increased Healthcare Expenditure Expands Access to Cutting-Edge Treatments
- Rising Investment in Biotechnology Spurs Growth in Novel Treatments
- Telemedicine and Remote Monitoring Technologies Propel Market Expansion
- Economic Burden of Myelofibrosis Strengthens Business Case for Effective Solutions
- Integration of Artificial Intelligence in Drug Discovery Spurs Market Growth
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Myelofibrosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Myelofibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Myelofibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: USA 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
JAPAN
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
CHINA
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: China Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: China 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
EUROPE
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Myelofibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Myelofibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
FRANCE
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: France Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: France 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
GERMANY
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: UK 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: Rest of Europe 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Myelofibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Asia-Pacific 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030
REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Rest of World Historic Review for Myelofibrosis Therapeutics by Therapy - Targeted Therapy, Chemotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Rest of World 16-Year Perspective for Myelofibrosis Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy and Other Therapies for the Years 2014, 2024 & 2030